Kristin A. Heath was named executive director of the University of Florida Health Proton Therapy Institute. Kristin A. Heath succeeds Stuart L. Klein, who retired in November 2023 after 18 years.
Ramez N. Eskander was named Clinical Trials Office director for oncology at UC San Diego Health and Moores Cancer Center. Eskander succeeds Sandip Patel.
David Swoboda was named clinical director of leukemia at Tampa General Hospital Cancer Institute.
The Convergent Science Cancer Consortium, a consortium using an unconventional approach that emphasizes the integration of diverse scientific disciplines, received a $3.2 million grant from the U.S. Department of Defense.
The University of New Mexico Comprehensive Cancer Center broke ground on a $61M clinic building addition that will enable it to offer treatments unavailable elsewhere in New Mexico.
Nationwide Children’s Hospital and The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute opened a $100 million, 55,000 square foot proton therapy center. It is the first treatment facility in central Ohio offering this highly targeted form of radiation therapy for treatment of complex tumors that cannot be removed through surgery.
Chef Chris Haatuft serves guests at the BCM Culinary Stars Shine for Cancer Research.Baylor College of Medicine’s Culinary Stars Shine for Cancer Research event raised $6.2 million to support cancer research at Baylor’s Dan L Duncan Comprehensive Cancer Center.
Care for patients with human papillomavirus (HPV)-related squamous cell cancers of the oropharynx (an area in back of the throat) is shifting toward community cancer centers, but patients treated in this setting may be less likely to survive, according to new research by investigators from the Johns Hopkins Kimmel Cancer Center and its Head and Neck Cancer Center.
Researchers from University of Pittsburgh and Washington University School of Medicine in St. Louis found that liquid from surgical drains, which is usually tossed in the trash, could inform more precise treatments for patients with head and neck cancer caused by human papillomavirus.
In a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), followed by dostarlimab plus Zejula (niraparib) as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer, the trial met its primary endpoint of progression-free survival.
